000126459 001__ 126459
000126459 005__ 20190415234759.0
000126459 037__ $$aBOOK_CHAP
000126459 245__ $$aCell therapy using encapsulated cells producing endostatin
000126459 269__ $$a2003
000126459 260__ $$bSpringer$$c2003$$aNew York, NY
000126459 336__ $$aBook Chapters
000126459 490__ $$aActa Neurochirurgica Supplementum$$v88
000126459 500__ $$aAuthor address: University of Bergen, Bergen, Norway
000126459 520__ $$aDespite aggressive surgery and post-operative radiation and chemotherapy, the prognosis is poor for glioblastoma patients. Anti-angiogenic therapy with compounds such as endostatin could delay the onset of relapse. However, the short systemic half-life of this proteins as well as the blood-brain barrier makes the use of this therapy difficult for brain cancer patients. The aim of this project is to develop and implant genetically engineered producer cells secreting endostatin that are encapsulated in calcium cross-linked alginate gel beads. Encapsulation of cells within alginate gels has a potential as a sustained release system in addition to the fact that the encapsulation technology protects the cells from rejection by the immune system. Human embryonal kidney 293 cells have been transfected with the gene for endostatin. These cells have been encapsulated in calcium cross-linked alginate gels and optimized for the secretion of endostatin. Alginate gel beads implanted into rat brain have shown only a moderate loss in cell viability but extended endostatin release for periods of up to 12 months. Visualization of the anti-angiogenic effect on C6 rat glioma growth, tumor vasculature and microhemodynamics has been demonstrated by using intravital video microscopy. The data indicates that endostatin greatly affects tumor-associated microcirculation but does not appear to affect normal microcirculation. The local delivery of endostatin seems to specifically affect tumor-associated microvessels by reduction of the vessel density, diameter and functionality. Tumor cell migration and invasion was greatly reduced in the endostatin treated animals
000126459 6531_ $$aAlginates
000126459 6531_ $$aAngiogenesis Inhibitors/administration & dosage/genetics/metabolism
000126459 6531_ $$aAnimals
000126459 6531_ $$aBrain Neoplasms/blood supply/drug therapy
000126459 6531_ $$aCapsules
000126459 6531_ $$aCell Line
000126459 6531_ $$aCell Transplantation
000126459 6531_ $$aDrug Delivery Systems
000126459 6531_ $$aEndostatins/administration & dosage/genetics/metabolism
000126459 6531_ $$aGene Targeting
000126459 6531_ $$aGlioma/blood supply/drug therapy
000126459 6531_ $$aHumans
000126459 6531_ $$aMicrocirculation/drug effects
000126459 6531_ $$aNeovascularization
000126459 6531_ $$aPathologic/drug therapy
000126459 6531_ $$aRats
000126459 6531_ $$aTransfection
000126459 700__ $$aBjerkvig, R.
000126459 700__ $$aRead, T. A.
000126459 700__ $$aVajkoczy, P.
000126459 700__ $$0240206$$g104359$$aAebischer, P.
000126459 700__ $$0241407$$g135489$$aPralong, W.
000126459 700__ $$aPlatt, S.
000126459 700__ $$aMelvik, J. E.
000126459 700__ $$aHagen, A.
000126459 700__ $$aDornish, M.
000126459 773__ $$tLocal Therapies for Glioma$$q137-141
000126459 909C0 $$xU10457$$0252067$$pLEN
000126459 909CO $$pbook$$pchapter$$ooai:infoscience.tind.io:126459$$pSV
000126459 937__ $$aLEN-CHAPTER-2008-005
000126459 973__ $$sPUBLISHED$$aEPFL
000126459 980__ $$aCHAPTER